Phase 1
Completed N=9
A Study of 18F-AV-45 in Healthy Volunteers
Source: ClinicalTrials.gov NCT01564706 ↗Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Apr 2012
Primary outcomePrimary: Whole Body Radiation Dosimetry — 0.0186; 0.0136; 0.01; 0.00624 mSv/MBq
Summary
This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Whole Body Radiation Dosimetry |
0.0186; 0.0136; 0.01; 0.00624; 0.143; 0.0278 | — |
Eligibility Criteria
Inclusion Criteria
- Able to lie still on the imaging table for periods up to 1 hour
Exclusion Criteria
- Radiation exposure for experimental purposes within the last year
- Claustrophobic or otherwise unable to tolerate the imaging procedure
- Medical condition or surgical history that would confound evaluation
- Current clinically significant cardiovascular disease
- Received an investigational medication within the last 30 days
Data sourced from ClinicalTrials.gov (NCT01564706). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.